Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.
from Reuters: Health https://reut.rs/2SGAiUx
via
IFTTT
0 comments: